コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of oxaliplatin neuropathy (a complication of cancer chemotherapy).
2 s cardioprotective therapeutic agents during cancer chemotherapy.
3 of proteins has proven a valid strategy for cancer chemotherapy.
4 promising therapeutic approach for prostate cancer chemotherapy.
5 ule-stabilizing agent that is widely used in cancer chemotherapy.
6 nblastine and vincristine, which are used in cancer chemotherapy.
7 ucleoside analogs for oral administration in cancer chemotherapy.
8 emotherapeutic drug release applications for cancer chemotherapy.
9 tion (EF) and volumes in patients undergoing cancer chemotherapy.
10 orable treatment outcomes in cisplatin-based cancer chemotherapy.
11 toxicity which remains a major limitation in cancer chemotherapy.
12 (SETMAR) mediates resistance to DNA damaging cancer chemotherapy.
13 ising approach to increasing the efficacy of cancer chemotherapy.
14 forts to target the CXCL12-CXCR4 pathway for cancer chemotherapy.
15 epresents a novel mitotic spindle target for cancer chemotherapy.
16 ole of hCtr1 in platinum-drug sensitivity in cancer chemotherapy.
17 resulting in an attenuated response to anti-cancer chemotherapy.
18 he further development of LSF inhibitors for cancer chemotherapy.
19 istance (MDR) is a major cause of failure of cancer chemotherapy.
20 n might be a simple yet effective adjunct to cancer chemotherapy.
21 s, including a variety of drugs used in anti-cancer chemotherapy.
22 DXR and identify RGS6 as a novel target for cancer chemotherapy.
23 (MDR) has decreased the hope for successful cancer chemotherapy.
24 ding the emergence of drug resistance during cancer chemotherapy.
25 resistance (MDR) is a barrier to successful cancer chemotherapy.
26 e-2,6-bisphosphatase, an emerging target for cancer chemotherapy.
27 Doxorubicin is widely used in breast cancer chemotherapy.
28 bition of SET may have beneficial effects in cancer chemotherapy.
29 he mitotic spindle is a validated target for cancer chemotherapy.
30 SUMO1 appears to be a new target pathway for cancer chemotherapy.
31 Febrile neutropenia commonly complicates cancer chemotherapy.
32 rs currently being sought as an adjuvant for cancer chemotherapy.
33 eed for new molecular targets for pancreatic cancer chemotherapy.
34 ymerization and shows remarkable efficacy in cancer chemotherapy.
35 PA) is a DNA alkylating agent widely used in cancer chemotherapy.
36 is linked to tumour multidrug resistance in cancer chemotherapy.
37 etic modification of Hy, stepping forward to cancer chemotherapy.
38 pase activation, thus having implications in cancer chemotherapy.
39 iated targeting of this pathway can optimize cancer chemotherapy.
40 that T115 is a potential drug candidate for cancer chemotherapy.
41 ure of both molecular diagnostics as well as cancer chemotherapy.
42 , thus representing an attractive target for cancer chemotherapy.
43 nhibitors can emerge as a unique paradigm in cancer chemotherapy.
44 resent a class of nucleoside analogs used in cancer chemotherapy.
45 y the Food and Drug Administration (FDA) for cancer chemotherapy.
46 lymerization inhibitors for potential use in cancer chemotherapy.
47 ar targets (molecular targets) important for cancer chemotherapy.
48 he variable efficacy of antimitotic drugs in cancer chemotherapy.
49 both p53 and Rb is important for efficacy of cancer chemotherapy.
50 ing normal tissue is critically important in cancer chemotherapy.
51 great potential to make a paradigm shift in cancer chemotherapy.
52 nt implications for the individualization of cancer chemotherapy.
53 DNA-damaging agents are extensively used for cancer chemotherapy.
54 livered dose intensity in patients receiving cancer chemotherapy.
55 of modulation of this signaling pathway for cancer chemotherapy.
56 nd ABCC1/MRP1 causes multidrug resistance in cancer chemotherapy.
57 taxel-induced neuropathic pain models during cancer chemotherapy.
58 itize ABCC1/MRP1-mediated drug resistance in cancer chemotherapy.
59 erior to angiostatin and may be exploited in cancer chemotherapy.
60 Paclitaxel is an active agent used in breast cancer chemotherapy.
61 represent major dose-limiting toxicities of cancer chemotherapy.
62 esistance is a serious problem in successful cancer chemotherapy.
63 tion, oxidative stress, and certain types of cancer chemotherapy.
64 lly valid marker of viable cell number after cancer chemotherapy.
65 rently being evaluated in clinical trials as cancer chemotherapy.
66 major success in the era of target-directed cancer chemotherapy.
67 ce and its potential modulation for improved cancer chemotherapy.
68 ounting for their widespread use in clinical cancer chemotherapy.
69 -gp) has been correlated with resistances in cancer chemotherapy.
70 ules has shown potential as a new avenue for cancer chemotherapy.
71 regulation and are an attractive target for cancer chemotherapy.
72 rent drugs, remains an unsolved challenge in cancer chemotherapy.
73 tors of DNA replication are commonly used in cancer chemotherapy.
74 tinues to be a major impediment to effective cancer chemotherapy.
75 uration of neutropenia in patients receiving cancer chemotherapy.
76 icin is an anthracycline antibiotic used for cancer chemotherapy.
77 f microtubules is an important mechanism for cancer chemotherapy.
78 that IDO inhibitors may improve responses to cancer chemotherapy.
79 substances that are of potential interest in cancer chemotherapy.
80 nes that may enable the individualization of cancer chemotherapy.
81 zyme in DNA synthesis and a major target for cancer chemotherapy.
82 ll and developmental biology, nutrition, and cancer chemotherapy.
83 duce apoptosis and may be exploited for anti-cancer chemotherapy.
84 inhibitors may be a powerful new approach to cancer chemotherapy.
85 exate is one of the most successful drugs in cancer chemotherapy.
86 development of an optimal ribonuclease-based cancer chemotherapy.
87 ide natural products that are widely used in cancer chemotherapy.
88 the major dose-limiting toxicity of systemic cancer chemotherapy.
89 erase inhibitors are a powerful strategy for cancer chemotherapy.
90 ult in the lack of efficacy of many drugs in cancer chemotherapy.
91 emonstrated the potential efficacy of TPA in cancer chemotherapy.
92 otic agent that has been used extensively in cancer chemotherapy.
93 ization for serious toxicity associated with cancer chemotherapy.
94 atin,is an important problem to be solved in cancer chemotherapy.
95 e that is associated with a poor response to cancer chemotherapy.
96 nd their validation as potential targets for cancer chemotherapy.
97 ational modification may serve as a possible cancer chemotherapy.
98 nding has significant implications for human cancer chemotherapy.
99 known about interactions of supplements with cancer chemotherapy.
100 quent and potentially severe complication of cancer chemotherapy.
101 r interstitium are of critical importance in cancer chemotherapy.
102 ntially nonimmunogenic approach for targeted cancer chemotherapy.
103 ve force to overcome multidrug resistance in cancer chemotherapy.
104 ntisense technology may play a major role in cancer chemotherapy.
105 y of topoisomerase II inhibitors in clinical cancer chemotherapy.
106 ceptibility to stress such as that caused by cancer chemotherapy.
107 nds for the development of isoform-selective cancer chemotherapy.
108 ar topoisomerase I is an important target in cancer chemotherapy.
109 r anticonvulsants compromise the efficacy of cancer chemotherapy.
110 several toxic agents including radiation and cancer chemotherapy.
111 hancing the effectiveness of these agents in cancer chemotherapy.
112 vity is emerging as an attractive target for cancer chemotherapy.
113 gs such as methotrexate are commonly used in cancer chemotherapy.
114 ess disease relapse after 5-FU-based gastric cancer chemotherapy.
115 epresents a promising strategy to potentiate cancer chemotherapy.
116 istance (MDR) is a major cause of failure in cancer chemotherapy.
117 e formation of multidrug resistance (MDR) in cancer chemotherapy.
118 ibitors that may also serve as new leads for cancer chemotherapy.
119 pment of antibody-drug conjugates (ADCs) for cancer chemotherapy.
120 ains a major challenge to successful ovarian cancer chemotherapy.
121 livery systems for targeted and personalized cancer chemotherapy.
122 ning is a promising avenue for innovation in cancer chemotherapy.
123 bjects, 36 of whom were scheduled to receive cancer chemotherapy.
124 ic uptake inhibitors treatment during breast cancer chemotherapy.
125 as cisplatin, have been used extensively in cancer chemotherapy.
126 jor factor limiting the continued success of cancer chemotherapy.
127 on is a promising new strategy for improving cancer chemotherapy.
128 mustards and mitomycin C, are used widely in cancer chemotherapy.
129 g well-defined metallo-helical complexes for cancer chemotherapy.
130 pharmacodynamic biomarkers for anti-mitotic cancer chemotherapy.
131 ells and as a promising target to potentiate cancer chemotherapy.
132 expense and some toxicity to adjuvant breast cancer chemotherapy.
133 er surgical procedures and immunosuppressing cancer chemotherapy.
134 d as an appealing alternative to traditional cancer chemotherapy.
135 mily, and continue to be extensively used in cancer chemotherapy.
136 Cisplatin is a mainstay of cancer chemotherapy.
137 in (DOX) is an anthracycline used widely for cancer chemotherapy.
138 ive fungal infections (IFIs) that complicate cancer chemotherapy.
139 st toxicity is one of the main challenges of cancer chemotherapy.
140 expression and represent valuable targets in cancer chemotherapy.
141 continue to deliver productive pipelines for cancer chemotherapy.
142 ins one of the most serious complications of cancer chemotherapy.
143 uced a patient cohort requiring both HIV and cancer chemotherapy.
144 ations for mechanisms of cell killing during cancer chemotherapy.
145 his frequently encountered adverse effect of cancer chemotherapies.
146 toxic side effects commonly associated with cancer chemotherapies.
147 kely to unravel additional targets for novel cancer chemotherapies.
148 d potentially enhance the efficacy of extant cancer chemotherapies.
149 ligible and provide insight into antimitotic cancer chemotherapies.
150 g delivery systems for personalized targeted cancer chemotherapies.
151 crease effectiveness of proteasome inhibitor cancer chemotherapies.
152 (ICL), a property exploited by several anti-cancer chemotherapies.
153 step toward studying the pharmacogenetics of cancer chemotherapy, 51 candidate genes from the pathway
154 ne of the most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer
156 Cisplatin is one of the most widely used cancer chemotherapy agents, but its mechanism of action
157 oxorubicin (DXR), among the most widely used cancer chemotherapy agents, promotes cancer cell death v
158 ing cassette transporters to the toxicity of cancer chemotherapy agents, we have used mice geneticall
159 associated with end-stage renal failure and cancer chemotherapy, also has pleiotropic properties.
160 al neuropathy is dose limiting in paclitaxel cancer chemotherapy and can result in both acute pain du
161 rentiation, and apoptosis, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(
162 ddress the problem of drug resistance during cancer chemotherapy and explore the possibility of manip
163 of polyamine levels is a viable strategy for cancer chemotherapy and for the treatment of parasitic d
165 how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacoki
167 n patients with short-bowel syndrome, during cancer chemotherapy and in bone marrow transplantation,
168 ance of tumours to alkylating agents used in cancer chemotherapy and its inactivation is therefore of
169 cyclines and etoposide are commonly used for cancer chemotherapy and kill tumor cells by causing accu
171 floxacin on cycle 1 only of myelosuppressive cancer chemotherapy and on subsequent cycles after a cyc
174 pproach may reduce both the doses needed for cancer chemotherapy and the side effects in tissues with
175 idrug efflux pumps cause serious problems in cancer chemotherapy and treatment of bacterial infection
176 activity is a common and successful tool in cancer chemotherapy and treatment of other diseases.
177 eful in combating the nausea associated with cancer chemotherapy, and alosetron is employed in the tr
178 ospitalization rate for toxicity from breast cancer chemotherapy, and even large clinical trials ofte
179 uman immunodeficiency virus (HIV) infection, cancer chemotherapy, and hematopoietic stem cell transpl
180 ighly tumorigenic, resistant to conventional cancer chemotherapy, and responsible, at least in part,
181 g: ICL-inducing agents are powerful tools in cancer chemotherapy, and spontaneous ICLs have recently
182 uently induced by medical treatments such as cancer chemotherapy, antirejection drugs used in organ t
183 ncapsulated drugs that have shown promise in cancer chemotherapy are administered intravenously.
187 ation of TR3 as a drug target for pancreatic cancer chemotherapy, based on the ability of TR3 inhibit
188 ylase (TP) is an important target enzyme for cancer chemotherapy because it is expressed at high leve
189 th some advances in modern medicine (such as cancer chemotherapy, broad exposure to antibiotics, and
190 ighly effective component of curative breast cancer chemotherapy but are associated with substantial
191 GART) (EC 2.1.2.2) is a validated target for cancer chemotherapy, but mechanistic studies of this the
192 (hTS) has been extensively investigated for cancer chemotherapy, but several aspects of its activity
193 ptotic bax gene may be a valuable adjunct to cancer chemotherapy by diminishing survival of p53-defic
194 onmental exposure, endogenous metabolism and cancer chemotherapy can give rise to alkylation of DNA,
195 inib, two agents already used clinically for cancer chemotherapy, can inhibit this activity suggest t
197 2 (HER2/NEU) signaling, a mainstay of breast cancer chemotherapy, cause dilated cardiomyopathy in man
198 rug delivery systems (DDSs), side effects of cancer chemotherapy could be reduced by using multifunct
200 tion damage resistance, which is critical in cancer chemotherapy, depends on the overexpression of al
203 We conjugate paclitaxel (PTX), a widely used cancer chemotherapy drug, to branched polyethylene glyco
206 e 3-kinase (PI3K) is an important target for cancer chemotherapy due to the deregulation of its signa
208 ration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone receptor (HR
211 hile combination therapies are a mainstay of cancer chemotherapy, few studies have addressed the comb
212 parameters in 1,504 patients during or after cancer chemotherapy for 3 clinically-relevant scenarios.
215 drugs have the potential to greatly advance cancer chemotherapy for new theranostics and drug-delive
218 Research on controlled drug delivery for cancer chemotherapy has focused mainly on ways to delive
219 tween individuals in the pharmacokinetics of cancer chemotherapy has important consequences in terms
220 trials employing synthetic MMP inhibitors in cancer chemotherapy has led us to hypothesize that some
221 ermal growth factor receptor as a target for cancer chemotherapy has proven to be an effective treatm
222 ine-DNA complex, which is a potent agent for cancer chemotherapy, has a unique intercalating molecula
224 DNA crosslinking agents are commonly used in cancer chemotherapy; however, responses of normal tissue
225 cern when these people are exposed to either cancer chemotherapy, immunosuppressive or biologic thera
226 nase I (HAI) is a potential protein drug for cancer chemotherapy, in that it is capable of depleting
227 B overexpression also mediated resistance to cancer chemotherapy, in this case through interactions w
230 ng therapeutic strategy for the treatment of cancer, chemotherapy-induced peripheral neuropathy, and
242 Medicare beneficiaries received recommended cancer chemotherapy less frequently than other Medicare
243 els have been a major therapeutic target for cancer chemotherapy, little is known regarding the stepw
245 mutations caused by cytotoxic agents used in cancer chemotherapy may cause secondary malignancies as
248 DS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use,
251 ecommended for persons with HBsAg undergoing cancer chemotherapy or transplantation, but major questi
254 In rats exposed to either of 2 neurotoxic cancer chemotherapies, paclitaxel or oxaliplatin, or to
255 C (PKC), a validated therapeutic target for cancer chemotherapy, provides a paradigm for assessing s
257 rall, 17.3% of the elderly women with breast cancer chemotherapy received filgrastim and 6.8% receive
258 taxanes are important components of prostate cancer chemotherapy regimens, but their oral administrat
261 , however their simultaneous role in ovarian cancer chemotherapy resistance remains poorly elucidated
262 ify potential mechanisms underlying prostate cancer chemotherapy response and resistance, we compared
263 pite its proven efficacy in treating ovarian cancer, chemotherapy seems to be used less among patient
265 ed as poor prognostic factors for successful cancer chemotherapy, strategies that use antiapoptotic f
266 a three-arm, phase III, advanced colorectal cancer chemotherapy study exploring combinations of irin
267 ession and that some conventional colorectal cancer chemotherapy supports the immunosuppressive tumor
268 eins (ATLs) share functional motifs with the cancer chemotherapy target O(6)-alkylguanine-DNA alkyltr
271 on surgical procedures and immunosuppressing cancer chemotherapies that rely on antibiotic prophylaxi
273 The two-drug model has implications for cancer chemotherapy, the cellular processing of etoposid
275 g clinical therapeutics in broad areas, from cancer chemotherapy to antipsychotics and antidepressant
277 cancer drugs is an emerging new strategy for cancer chemotherapy to increase antitumor responses.
282 ularly relevant to cancer treatment, as most cancer chemotherapies trigger mitochondrial-mediated apo
285 of febrile neutropenia in patients receiving cancer chemotherapy utilizing the myeloid growth factors
286 ment of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X(L) function
287 g women with LN-positive, ER-negative breast cancer, chemotherapy was associated with a significant r
289 To reveal the antiangiogenic capability of cancer chemotherapy, we developed an alternative antiang
291 th acquired drug resistance against standard cancer chemotherapies were more sensitive to WL-276 than
293 plantation, treatment of preterm babies, and cancer chemotherapy, which we today take for granted, wo
294 bitors have received regulatory approval for cancer chemotherapy while many others are in clinical de
295 cancer growth and are potential targets for cancer chemotherapy with ASCT2 (SLC1A5) being investigat
296 esin Eg5 is a target for drug development in cancer chemotherapy with compounds in phase II clinical
298 tion may identify a unique mechanism whereby cancer chemotherapy with receptor tyrosine kinase inhibi
299 further validated them as potential foci for cancer chemotherapy, with several additional PI3K effect
300 is the most commonly used drug in colorectal cancer chemotherapy, yet development of drug resistance